reported a narrower third-quarter loss thanks to strong sales of its drug Ventavis for pulmonary arterial hypertension.
Shares were up 95 cents, or 13%, to $8.28.
The company lost $2.8 million, or 10 cents a share, in the quarter, compared with a loss of $6.2 million, or 26 cents a share, in the year-ago period.
Excluding the impact of stock-based compensation expenses and amortization of deferred stock compensation a year ago, CoTherix would have lost $1.1 million, or 4 cents a share, in the third quarter compared with a loss of $5.1 million, or 22 cents a share, a year ago.
Sales were $18.4 million, more than double last year.
The company issued 2007 sales guidance of between $100 million and $105 million. However, analysts were expecting $107 million in sales next year.